← Leaderboards
Roger Crystal
Opiant Pharmaceuticals, Inc.
$7,387,573
Attributed
$7,387,573
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2018–21$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
Funding mix
By agency
NIH$7,387,573 · 1
By mechanism
U01$7,387,573 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Affinity”
- Bala Raja · Luminostics, Inc.$28,624,460
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$25,726,378
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Timothy M Willson · University Of Cape Town$13,865,323
Research focus
AffinityAmericanCessation Of LifeCustomEmergency Medical ServiceEmergency SituationExposure ToFamilyFda ApprovedFentanylFirst ResponderFormulationFriendsHalf-LifeHeroinHeroin UseHospitalsHuman ResourcesInjectionsLaw EnforcementLinkMarketingNalmefeneNaloxone
Grant awards (3)
Development of an intranasal, long duration opioid antagonist to treat opioid overdose$1,800,581
U01 · FY2021 · DA · contact PI
Development of an intranasal, long duration opioid antagonist to treat opioid overdose$3,035,646
U01 · FY2019 · DA · contact PI
Development of an intranasal, long duration opioid antagonist to treat opioid overdose$2,551,346
U01 · FY2018 · DA · contact PI